Advanced Oncotherapy – Director Dealing & Total Voting Rights

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, has been informed that Michael Sinclair, Executive Chairman of the Company, has yesterday sold 7 million ordinary shares of 1 penny each in the Company at 8.25 pence per Share in order to fund the exercise of warrants over 28.5 million Shares at an exercise price of 1.1 pence per Share.

The remainder of the funds raised from Mr Sinclair’s share sale will be used to fund the acquisition of the option over 30 million Shares from Brahma A.G., which was announced of 4 June 2015.

Michael Sinclair’s resultant increased interest in the Company ordinary share capital is as follows:

Following these transactions Michael Sinclair does not hold any further warrants over Shares.

Application has been made for the 28,500,000 Warrant Shares to be admitted to trading on AIM and it is expected that Admission will occur on 7 July 2015. The Warrant Shares will rank pari passu in all respect with the existing Shares of the Company.

Total Voting Rights:

Following Admission, the Company’s enlarged issued share capital will comprise 1,376,422,626 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,376,422,626. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information contact: